DWQA Questions › Tag: chelation therapy 2
Filter:AllOpenResolvedClosedUnanswered
The trial to assess chelation therapy 2 (TACT2) on cardiovascular outcomes in patients with diabetes and a prior myocardial infarction (MI) was reported in September, 2024. While there was a significant reduction in circulating heavy metals following months of weekly intravenous EDTA infusions, there was not a significant reduction in cardiovascular events or mortality. You told us previously that EDTA therapy was actually beneficial, as the first TACT study showed, but that the interlopers were suppressing beneficial clinical data. Is that the reason for the failed confirmation with the TACT2 follow-up?
ClosedNicola asked 19 hours ago • 
9 views0 answers0 votes
Ask Question